Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes

被引：25
作者：
Ishida, Kazuya [1 ]
Taira, Shigehiro [1 ]
Morishita, Hiroki [1 ]
Kayano, Yuichiro [1 ]
Taguchi, Masato [1 ]
Hashimoto, Yukiya [1 ]
机构：
[1] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Toyama 9300194, Japan
来源：
BIOLOGICAL & PHARMACEUTICAL BULLETIN | 2008年 / 31卷 / 06期
关键词：
carvedilol; stereoselective metabolism; liver; intestine;
D O I：
10.1248/bpb.31.1297
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The aim of the present study was to investigate the mechanism for the stereoselective presystemic clearance of carvedilol. We examined the oxidation and glucuronidation of carvedilol in human liver microsomes (HLM) and human intestinal microsomes (HIM). The oxidation of carvedilol in HLM and HIM was evaluated in the presence of NADPH, whereas glucuronidation was evaluated in the presence of UDP-glueuronic acid. Oxidation of S-carvedilol in HLM and HIM was greater than that of R-carvedilol. In addition, the oxidation of R-carvedilol in HLM was inhibited by quinidine, whereas that of S-carvedilol was inhibited by both quinidine and furafylline. On the other hand, R- and S-carvedilol oxidation in HIM vas inhibited by ketoconazole. Glucuronidation of S-carvedilol in HLM and HIM was also higher than that of R-carvedilol. These results suggested that cytochrome P450 (CVP) 2D6 and CYP1A2 are involved in the stereoselective oxidation of carvedilol in the liver, that CYP3A4 is involved in intestinal oxidation, and that glucuronidation in the liver and intestine is at least partly responsible for stereoselective presystemic clearance.
引用
收藏
页码：1297 / 1300
页数：4
相关论文
共 16 条
  • [1] EGGERTSEN R, 1987, Journal of Cardiovascular Pharmacology, V10, pS97, DOI 10.1097/00005344-198710111-00018
  • [2] ASSAY AND DISPOSITION OF CARVEDILOL ENANTIOMERS IN HUMANS AND MONKEYS - EVIDENCE OF STEREOSELECTIVE PRESYSTEMIC METABOLISM
    FUJIMAKI, M
    MURAKOSHI, Y
    HAKUSUI, H
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (07) : 568 - 572
  • [3] Multiple regression analysis of pharmaeogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers
    Honda, M
    Ogura, Y
    Toyoda, W
    Taguchi, M
    Nozawa, T
    Inoue, H
    Hashimoto, Y
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (04) : 772 - 778
  • [4] Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers
    Honda, M
    Nozawa, T
    Igarashi, N
    Inoue, H
    Arakawa, R
    Ogura, Y
    Okabe, H
    Taguchi, M
    Hashimoto, Y
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (08) : 1476 - 1479
  • [5] Stereoselective metabolism of carvedilol by the β-naphthoflavone-inducible enzyme in human intestinal epithelial caco-2 cells
    Ishida, Kazuya
    Honda, Mutsuko
    Shimizu, Takako
    Taguchi, Masato
    Hashimoto, Yukiya
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (10) : 1930 - 1933
  • [6] Combination therapy with carvedilol and amiodarone in patients with severe heart failure
    Nägele, H
    Bohlmann, M
    Eck, U
    Petersen, B
    Rödiger, W
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2000, 2 (01) : 71 - 79
  • [7] A COMPARISON OF CARVEDILOL WITH A COMBINATION OF PROPRANOLOL AND ISOSORBIDE DINITRATE IN THE CHRONIC TREATMENT OF STABLE ANGINA
    NAHRENDORF, W
    RADING, A
    STEINIG, G
    VANDERDOES, R
    SCHLOTE, A
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 19 : S114 - S116
  • [8] NEUGEBAUER G, 1987, Journal of Cardiovascular Pharmacology, V10, pS85
  • [9] NEWTON DJ, 1995, DRUG METAB DISPOS, V23, P154
  • [10] Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol
    Ohno, A
    Saito, Y
    Hanioka, N
    Jinno, H
    Saeki, M
    Ando, M
    Ozawa, S
    Sawada, J
    [J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (02) : 235 - 239
12